Special Issue "Surviving, Striving, Thriving: Exploring Extracellular Vesicles as Key Drivers of Cancer Cell Survival, Resistance and Relapse"
Deadline for manuscript submissions: 20 December 2023 | Viewed by 2393
Interests: leukaemia; cancer cell dormancy; drug resistance; measurable residual disease; liquid biopsy & cancer biomarkers; stress response; microenvironment-dependent drug resistance; organ-on-a-chip; bioengineered 3D microenvironments
Extracellular vesicles (EVs) are nanosized lipid membrane-enclosed vesicles that mediate intercellular signaling to coordinate the most complex physiological processes. Unsurprisingly, EV signaling networks are consistently transformed through the carcinogenesis process. Indeed, there is accumulating evidence strongly suggestive of the notion that cancers’ modus operandi for thriving are highly reliant on EV-mediated intercellular communication. Contrary to the once-prevalent dogma of “drug resistance by cancer genetics”, it has now become apparent that, for most cases, drug resistance seems to emerge from non-genetic changes at the tumor microenvironment. Importantly, these advantageous non-genetic features are conferred by EVs—occurring both in tumor and stromal cells—and enable cancer cells to adapt, survive drug exposure, relapse and metastasize later. Most interestingly, this EV dependency hallmark of cancer cells seems to hold true for many (if not all) human solid and liquid malignancies.
Thus, a timely and comprehensive understanding of how cancer-associated EVs enables tumor initiation, progression, drug resistance and relapse is instrumental for the development of innovative approaches that can have a transformative impact on both the early diagnosis and outcome of cancer treatment.
We invite you to contribute original research, technical notes, methods papers, and/or reviews to this Special Issue of “Surviving, Striving, Thriving: Exploring Extracellular Vesicles as Key Drivers of Cancer Cell Survival, Resistance and Relapse”. Papers that cover advances in the methods of cancer-associated EV isolation, analysis of the role of these vesicles in perpetuating cancer hallmarks, as well as their implementation both in basic research and the translational field of cancer biomarkers will be enthusiastically received by our readership. This Special Issue will aim to highlight significant advancements in understanding the intricate EV signaling networks that enable cancer cells to thrive, even under most adverse therapeutic pressure.
Dr. Hugo Ronaldo Freitas Caires
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer hallmarks
- tumor microenvironment
- drug resistance
- solid & hematologic malignancies